All In Biotech

Drug Trial Radar · NCT07440524

A Phase 2 Trial of JKN24011 in COPD

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 215 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

215

Actual

Start

Aug 1, 2024

Primary completion

Apr 2, 2026

Study completion Apr 2, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • JKN24011Biological

    JKN24011 subcutaneous injection,Q4W

  • PlaceboOther

    Placebo subcutaneous injection,Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualised rate of moderate or severe COPD exacerbationsTime frame: Through the 52-week treatment period
  2. Annualised rate of moderate or severe COPD exacerbationsTime frame: Through the 28-week treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huadong Hospital, Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.